(ZNTL) Zentalis Pharmaceuticals - Overview
Stock: Azenosertib, ZN-C3-001, MAMMOTH
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 158% |
| Relative Tail Risk | -13.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | 15.16 |
| Character TTM | |
|---|---|
| Beta | 1.661 |
| Beta Downside | 1.601 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.54% |
| CAGR/Max DD | -0.55 |
Description: ZNTL Zentalis Pharmaceuticals January 19, 2026
Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a clinical-stage biotech focused on small-molecule oncology drugs. Its lead asset, azenosertib, is currently in a pivotal Phase 3 trial for ovarian cancer and is also being evaluated in Phase 1/2 studies for PARP-inhibitor-resistant disease (MAMMOTH) and other solid tumors (ZN-c3-001). The company operates under licensing and collaboration agreements with Recurium IP Holdings and is headquartered in San Diego, having been incorporated in 2014.
Key quantitative points (as of the most recent quarterly filing) include a cash runway of roughly $120 million, a quarterly R&D spend of about $30 million (≈ 25 % of total expenses), and a market-cap near $400 million, placing Zentalis in the lower-mid tier of U.S. biotech peers. The broader oncology biotech sector is driven by a CAGR of ~ 12 % in global cancer-drug sales, while the prevalence of PARP-inhibitor resistance creates a niche market estimated at $1–2 billion annually-an economic tailwind for agents like azenosertib. However, the company’s valuation is highly sensitive to Phase 3 readout timing and the competitive landscape of DNA-damage response inhibitors.
If you want a data-rich, unbiased view of Zentalis’s risk-adjusted upside, a quick look at ValueRay’s analyst dashboard can help you surface the most relevant metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -149.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -2.75 > 1.0 |
| NWC/Revenue: 934.8% < 20% (prev 809.6%; Δ 125.2% < -1%) |
| CFO/TA -0.41 > 3% & CFO -134.0m > Net Income -149.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.1m) vs 12m ago 1.45% < -2% |
| Gross Margin: 97.25% > 18% (prev 0.97%; Δ 9628 % > 0.5%) |
| Asset Turnover: 6.91% > 50% (prev 9.47%; Δ -2.56% > 0%) |
| Interest Coverage Ratio: -36.53 > 6 (EBITDA TTM -144.6m / Interest Expense TTM 3.98m) |
Altman Z'' -15.00
| A: 0.77 (Total Current Assets 288.3m - Total Current Liabilities 37.2m) / Total Assets 327.2m |
| B: -3.53 (Retained Earnings -1.16b / Total Assets 327.2m) |
| C: -0.37 (EBIT TTM -145.5m / Avg Total Assets 389.0m) |
| D: -15.54 (Book Value of Equity -1.16b / Total Liabilities 74.4m) |
| Altman-Z'' Score: -25.32 = D |
What is the price of ZNTL shares?
Over the past week, the price has changed by -11.95%, over one month by +61.31%, over three months by +64.93% and over the past year by +3.27%.
Is ZNTL a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZNTL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.3 | 140.3% |
| Analysts Target Price | 5.3 | 140.3% |
| ValueRay Target Price | 1.6 | -27.6% |
ZNTL Fundamental Data Overview February 05, 2026
P/B = 0.7221
Revenue TTM = 26.9m USD
EBIT TTM = -145.5m USD
EBITDA TTM = -144.6m USD
Long Term Debt = 36.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.07m USD (from shortTermDebt, last fiscal year)
Debt = 36.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.36m USD (from netDebt column, last quarter)
Enterprise Value = -61.4m USD (182.6m + Debt 36.7m - CCE 280.7m)
Interest Coverage Ratio = -36.53 (Ebit TTM -145.5m / Interest Expense TTM 3.98m)
EV/FCF = 0.46x (Enterprise Value -61.4m / FCF TTM -134.0m)
FCF Yield = 218.3% (FCF TTM -134.0m / Enterprise Value -61.4m)
FCF Margin = -498.8% (FCF TTM -134.0m / Revenue TTM 26.9m)
Net Margin = -555.8% (Net Income TTM -149.3m / Revenue TTM 26.9m)
Gross Margin = 97.25% ((Revenue TTM 26.9m - Cost of Revenue TTM 739.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.19 (set to none) (Enterprise Value -61.4m / Total Assets 327.2m)
Interest Expense / Debt = 16.21% (Interest Expense 5.95m / Debt 36.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -115.0m (EBIT -145.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.76 (Total Current Assets 288.3m / Total Current Liabilities 37.2m)
Debt / Equity = 0.15 (Debt 36.7m / totalStockholderEquity, last quarter 252.9m)
Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -2.36m / EBITDA -144.6m)
Debt / FCF = 0.02 (negative FCF - burning cash) (Net Debt -2.36m / FCF TTM -134.0m)
Total Stockholder Equity = 290.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.39% (Net Income -149.3m / Total Assets 327.2m)
RoE = -51.49% (Net Income TTM -149.3m / Total Stockholder Equity 290.0m)
RoCE = -44.55% (EBIT -145.5m / Capital Employed (Equity 290.0m + L.T.Debt 36.7m))
RoIC = -39.65% (negative operating profit) (NOPAT -115.0m / Invested Capital 290.0m)
WACC = 12.17% (E(182.6m)/V(219.3m) * Re(12.04%) + D(36.7m)/V(219.3m) * Rd(16.21%) * (1-Tc(0.21)))
Discount Rate = 12.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.97%
Fair Price DCF = unknown (Cash Flow -134.0m)
EPS Correlation: 68.67 | EPS CAGR: 35.15% | SUE: 1.28 | # QB: 1
Revenue Correlation: 24.48 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=-0.070 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.81 | Chg30d=-0.208 | Revisions Net=+3 | Growth EPS=+6.7% | Growth Revenue=+0.0%